IL304320A - Combined therapy that includes a Jack pathway inhibitor and a Sela inhibitor - Google Patents

Combined therapy that includes a Jack pathway inhibitor and a Sela inhibitor

Info

Publication number
IL304320A
IL304320A IL304320A IL30432023A IL304320A IL 304320 A IL304320 A IL 304320A IL 304320 A IL304320 A IL 304320A IL 30432023 A IL30432023 A IL 30432023A IL 304320 A IL304320 A IL 304320A
Authority
IL
Israel
Prior art keywords
inhibitor
combination therapy
jak pathway
rock
pathway inhibitor
Prior art date
Application number
IL304320A
Other languages
English (en)
Hebrew (he)
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of IL304320A publication Critical patent/IL304320A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL304320A 2021-01-11 2023-07-09 Combined therapy that includes a Jack pathway inhibitor and a Sela inhibitor IL304320A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163135969P 2021-01-11 2021-01-11
US202163253384P 2021-10-07 2021-10-07
PCT/US2022/011756 WO2022150676A1 (en) 2021-01-11 2022-01-10 Combination therapy comprising jak pathway inhibitor and rock inhibitor

Publications (1)

Publication Number Publication Date
IL304320A true IL304320A (en) 2023-09-01

Family

ID=80119468

Family Applications (1)

Application Number Title Priority Date Filing Date
IL304320A IL304320A (en) 2021-01-11 2023-07-09 Combined therapy that includes a Jack pathway inhibitor and a Sela inhibitor

Country Status (11)

Country Link
US (2) US11918581B2 (https=)
EP (1) EP4274578A1 (https=)
JP (1) JP2024503021A (https=)
KR (1) KR20230157307A (https=)
AU (1) AU2022206313A1 (https=)
CA (1) CA3207859A1 (https=)
CL (2) CL2023002004A1 (https=)
IL (1) IL304320A (https=)
MX (1) MX2023008141A (https=)
TW (1) TW202237083A (https=)
WO (1) WO2022150676A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11992490B2 (en) 2019-10-16 2024-05-28 Incyte Corporation Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP)
WO2024153147A1 (zh) * 2023-01-18 2024-07-25 北京普祺医药科技股份有限公司 一种氮杂环烷烃化合物、药物组合物及其用途

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005723A1 (fr) 1988-11-24 1990-05-31 Yoshitomi Pharmaceutical Industries, Ltd. Composes de trans-4-amino(alkyl)-1-pyridylcarbamoylcyclohexane et leur utilisation en medecine
ATE289815T1 (de) 1995-12-21 2005-03-15 Alcon Lab Inc Verwendung von substituierten isochinolinsulfonyl-verbindungen zur herstellung eines medikaments für die behandlung von glaukom und okularer ischämie
BR9711154A (pt) 1996-08-12 1999-08-17 Yoshitomi Pharmaceutical Agente farmac-utico contendo inibidor cinase rho
HRP20000495B1 (en) 1998-02-04 2005-12-31 Banyu Pharmaceutical Co. N-acyl cyclic amine derivatives
JP4212149B2 (ja) 1998-06-11 2009-01-21 株式会社デ・ウエスタン・セラピテクス研究所 医薬
CA2307285C (en) 1998-08-17 2009-03-31 Senju Pharmaceutical Co., Ltd. Agent for prophylaxis and treatment of glaucoma
US7217722B2 (en) 2000-02-01 2007-05-15 Kirin Beer Kabushiki Kaisha Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
KR100786927B1 (ko) 2000-06-28 2007-12-17 스미스클라인비이참피이엘시이 습식 분쇄방법
UY27224A1 (es) 2001-03-23 2002-10-31 Bayer Corp Inhibidores de la rho-quinasa
PE20020958A1 (es) 2001-03-23 2002-11-14 Bayer Corp Inhibidores de la rho-quinasa
WO2002100833A1 (en) 2001-06-12 2002-12-19 Sumitomo Pharmaceuticals Company, Limited Rho KINASE INHIBITORS
CA2556589A1 (en) 2004-02-24 2005-09-01 Bioaxone Therapeutique Inc. 4-substituted piperidine derivatives
TWI367098B (en) 2004-12-23 2012-07-01 Kowa Co Treating agent for glaucoma
SG10202003901UA (en) 2005-12-13 2020-05-28 Incyte Holdings Corp Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
KR20150036210A (ko) 2007-06-13 2015-04-07 인사이트 코포레이션 야누스 키나제 억제제（Ｒ）―３―（４―（７Ｈ―피롤로［２，３－ｄ］피리미딘―4―일）―1Ｈ―피라졸―1―일）―３―사이클로펜틸프로판니트릴의 염
EP3828172A1 (en) 2009-05-01 2021-06-02 Aerie Pharmaceuticals, Inc. Dual mechanism inhibitors for the treatment of disease
AR076794A1 (es) 2009-05-22 2011-07-06 Incyte Corp Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo [2,3-d]pirimidinas y pirrol-3-il-pirrolo [2,3-d ]pirimidinas como inhibidores de la quinasa janus y composiciones farmaceuticas que los contienen
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
EP3354652B1 (en) 2010-03-10 2020-05-06 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as jak1 inhibitors
US9034884B2 (en) 2010-11-19 2015-05-19 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
PE20140146A1 (es) 2010-11-19 2014-02-06 Incyte Corp Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak
CN103797010B (zh) 2011-06-20 2016-02-24 因塞特控股公司 作为jak抑制剂的氮杂环丁烷基苯基、吡啶基或吡嗪基甲酰胺衍生物
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
HRP20250965T1 (hr) 2012-06-15 2025-10-10 Sun Pharmaceutical Industries, Inc. Deuterirani derivati ruksolitiniba
WO2014028756A1 (en) 2012-08-17 2014-02-20 Concert Pharmaceuticals, Inc. Deuterated baricitinib
PL2903618T3 (pl) 2012-10-05 2022-09-19 Kadmon Corporation, Llc Inhibitory kinazy rho
TWI646099B (zh) 2012-11-01 2019-01-01 英塞特控股公司 作爲ｊａｋ抑制劑之三環稠合噻吩衍生物
RS62867B1 (sr) 2013-03-06 2022-02-28 Incyte Holdings Corp Postupci i intermedijeri za dobijanje inhibitora jak
HUE033587T2 (hu) 2013-05-17 2017-12-28 Incyte Corp Bipirazol-származékok mint JAK inhibitorok
SMT202000315T1 (it) 2013-08-07 2020-07-08 Incyte Corp Forme di dosaggio a rilascio prolungato per un inibitore di jak1
MA39987A (fr) 2014-04-30 2017-03-08 Incyte Corp Procédés de préparation d'un inhibiteur de jak1 et nouvelles formes associées
WO2020181034A1 (en) * 2019-03-05 2020-09-10 Incyte Corporation Jak1 pathway inhibitors for the treatment of chronic lung allograft dysfunction

Also Published As

Publication number Publication date
JP2024503021A (ja) 2024-01-24
US20240293411A1 (en) 2024-09-05
CL2024000773A1 (es) 2024-09-23
AU2022206313A1 (en) 2023-08-31
CL2023002004A1 (es) 2023-12-15
US11918581B2 (en) 2024-03-05
KR20230157307A (ko) 2023-11-16
US20220226327A1 (en) 2022-07-21
TW202237083A (zh) 2022-10-01
WO2022150676A1 (en) 2022-07-14
CA3207859A1 (en) 2022-07-14
EP4274578A1 (en) 2023-11-15
MX2023008141A (es) 2023-10-20

Similar Documents

Publication Publication Date Title
ZA202106511B (en) Jak inhibitor compound and use thereof
ES3063562T3 (en) Combination therapy including a kras-g12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
IL304320A (en) Combined therapy that includes a Jack pathway inhibitor and a Sela inhibitor
IL283598A (en) Combined treatment with radio-immune conjugates and a checkpoint inhibitor
IL274136A (en) Compressed sensing of electrograms coordinated in space and time and/or processed by graphs
GB202019475D0 (en) Therapeutic compounds and their use
GB202108572D0 (en) Therapeutic compounds and their use
ZA202210488B (en) Therapeutic lighting devices and methods
IL313081A (en) New HDAC inhibitors and their medical use
EP4186908C0 (en) JAK INHIBITOR COMPOUND AND ITS USE
GB202113079D0 (en) New therapy
IL281303B1 (en) Combination therapy of pimpinostat and PD-1 signaling inhibitor
IL304223A (en) combined treatment
IL309243A (en) Radioimmunoconjugates and combination therapy with barrier surveillance
IL309878A (en) Therapeutic compounds and methods
HK40102251A (en) Combination therapy comprising jak pathway inhibitor and rock inhibitor
GB202104037D0 (en) Combination therapy
GB202004189D0 (en) Combination therapy
IL309240A (en) Triple combined treatment
GB202111288D0 (en) Combination therapy
IL325938A (en) Combination therapy including BTK inhibitor and BELUMOSUDIL
GB202109087D0 (en) Therapeutic methods and devices
GB202015755D0 (en) Coronavirus therapy
HK40109325A (en) Radioimmunoconjugates and checkpoint inhibitor combination therapy
GB202018468D0 (en) New therapy